Skip to main content
Cutia Therapeutics logo

Cutia Therapeutics — Investor Relations & Filings

Ticker · 2487 ISIN · KYG2606C1006 HKEX Manufacturing
Open in API
Filings indexed 178 across all filing types
Latest filing 2024-07-03 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2487

About Cutia Therapeutics

http://www.cutiatx.com

Cutia Therapeutics is an R&D-driven biopharmaceutical platform established in 2019, specializing in the research, development, manufacture, and commercialization of dermatological treatments. The company is dedicated to providing a comprehensive suite of innovative, safe, and effective solutions for patients and consumers. Its core therapeutic focus areas include the management of localized adipose accumulation and various scalp diseases. As a dermatology-focused entity, Cutia maintains a dedicated pipeline emphasizing novel candidates, including those targeting the Immune System domain.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2024
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 30 June 2024. It details movements in authorised share capital, issued shares, share options, and confirms compliance with listing rules. It is a regulatory submission to the Hong Kong Exchanges and Clearing Limited, reporting share capital and share movements for a specific month. It does not contain financial statements, earnings data, or management discussion. It is a regulatory filing reporting share capital movements and confirmations related to securities issuance and compliance. Therefore, it fits best under Regulatory Filings (RNS).
2024-07-03 English
VOLUNTARY ANNOUNCEMENT - LAST PATIENT ENROLLED IN THE PHASE II CLINICAL TRIAL OF CU-20401 (RECOMBINANT MUTANT COLLAGENASE) FOR SUBMENTAL ADIPOSE ACCUMULATION
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Cutia Therapeutics regarding the last patient enrolled in a Phase II clinical trial for a drug candidate. It is a business update about clinical trial progress, not a financial report, regulatory filing, or meeting-related document. The text is relatively short (2939 characters) and does not contain financial data, voting results, or management changes. It is an operational update about drug development progress, which does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. The best fitting category is a general Regulatory Filings (RNS) as a fallback for miscellaneous announcements that do not fit other specific categories.
2024-06-28 English
VOLUNTARY ANNOUNCEMENT - RESULTS OF PHASE III CLINICAL TRIAL OF CU-10201 (TOPICAL 4% MINOCYCLINE FOAM) IN THE PRC ACCEPTED FOR E-POSTER PRESENTATION AT THE 29TH ANNUAL MEETING OF CSD
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Cutia Therapeutics regarding the acceptance of clinical trial results for e-poster presentation at a medical conference. It discusses the Phase III clinical trial results of a drug and provides safety and efficacy data. There is no indication that this is a full financial report, earnings release, or regulatory filing related to financial performance. The document is an announcement of business progress and clinical trial results, not a financial or regulatory report. It is also not a report publication announcement since it does not mention the release or availability of a report but rather announces clinical trial results acceptance for presentation. Therefore, the best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2024-06-28 English
OPERATIONAL UPDATE FOR THE FIRST QUARTER OF 2024
Regulatory Filings Classification · 95% confidence The document is an announcement titled 'OPERATIONAL UPDATE FOR THE FIRST QUARTER OF 2024' by the board of Cutia Therapeutics. It provides preliminary unaudited sales performance data for Q1 2024, explicitly stating that the data do not represent full earnings or financial performance and are based on draft unaudited operational data. The document is relatively short (2238 characters) and serves as an update rather than a comprehensive financial report. It does not contain full financial statements or detailed analysis typical of an Interim/Quarterly Report (IR). Instead, it is an operational update announcement providing preliminary business performance information. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2024-06-27 English
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 5 JUNE 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 5 JUNE 2024' and contains detailed voting results for resolutions passed at the AGM, including re-election of directors, approval of financial statements, appointment of auditors, and mandates related to share repurchase and issuance. It does not contain the full annual report or financial statements but reports the official voting outcomes of the AGM. The document length is 5640 characters, which is sufficient to include detailed poll results but not the full report. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements (DVA)', which covers official results from shareholder votes at any general meeting. Therefore, the correct classification is DVA.
2024-06-05 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2024
Regulatory Filings Classification · 95% confidence The document is a detailed monthly return on movements in securities for an equity issuer listed on the Hong Kong Stock Exchange, specifically under Chapter 19B of the Exchange Listing Rules. It includes information on authorized and issued share capital, share options, and confirmations related to securities issuance. The document is a regulatory submission to the Hong Kong Exchanges and Clearing Limited, reporting on share capital and share movements for the month ended 31 May 2024. It does not contain financial statements, earnings data, or management discussion, nor is it an announcement of a report publication. It is a regulatory filing reporting share capital and securities movements, which fits the category of Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories like Share Issue/Capital Change (SHA) because it is a monthly return report rather than a specific capital change event.
2024-06-05 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.